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OBJECTIVE — Type 2 diabetes increases risk of stroke, perhaps because of impaired cere-
brovascularbasalnitricoxide(NO)activity.Weinvestigatedwhetherthisactivityisimprovedby
a 2-week course of the xanthine oxidase inhibitor allopurinol.
RESEARCH DESIGN AND METHODS — We performed a randomized, double-blind,
placebo-controlledcrossoverstudy.WemeasuredtheresponsetoinfusionofNG-monomethyl-
L-arginine (L-NMMA) in males with type 2 diabetes before and after allopurinol or placebo. The
primary end point was the change in internal carotid artery ﬂow following L-NMMA infusion,
expressed as the area under the ﬂow-per-time curve.
RESULTS — Weenrolled14participants.Allopurinolimprovedresponsesto L-NMMAwhen
compared with responses associated with placebo (P  0.032; median reduction in internal
carotid artery ﬂow following L-NMMA of 3,144 ml [95% CI 375–7,143]).
CONCLUSIONS — Xanthine oxidase inhibition with allopurinol appears to improve cere-
bral NO bioavailability, as evidenced by a greater response to infusion of L-NMMA.
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T
ype 2 diabetes conveys an increased
riskofstroke(1,2),perhapsbecause
of impaired cerebrovascular basal
nitric oxide (NO) bioavailability—a hy-
pothesis suggested by impaired response
to infusion of the endothelial NO syn-
thase inhibitor NG-monomethyl-L-
arginine (L-NMMA) (3). We performed a
randomized, double-blind, placebo-
controlledcrossoverstudytotestwhether
this response is improved following a
course of the xanthine oxidase inhibitor
allopurinol.
RESEARCH DESIGN AND
METHODS— The study was ap-
proved by the West Medical research eth-
ics. Male patients aged 40 years with
type 2 diabetes of duration 5 years and
A1C 9.0% were studied. Those with se-
vere extracranial internal carotid artery
(ICA)stenosis,knownascoronaryarterial
disease, and those receiving insulin were
excluded. All gave written informed con-
sent and underwent exercise tolerance
testing (ETT) to exclude subclinical coro-
nary arterial disease.
Baseline assessment of ICA ﬂow and
middle cerebral artery mean ﬂow velocity
was performed. Peripheral (radial) pulse-
wave analysis (PWA) and (carotid-radial)
pulse-wave velocity (PWV) were mea-
sured. Blood was drawn for measurement
of routine parameters and vascular endo-
thelial growth factor, soluble intercellular
adhesion molecules, E-selectin, and C-re-
active protein levels. Thereafter, a 45-ml
infusion of 0.8 mol   kg
1   min
1 clin-
ical-grade L-NMMA (Clinalfa/Bachem-
Ag, Weil-am-Rhein, Germany) dissolved
in normal saline was given intravenously
over 15 min. ICA, middle cerebral artery,
PWA, and PWV parameters were re-
peateduponcessationofinfusionand10,
20, and 30 min thereafter.
Participants were then randomized to
either 300 mg allopurinol or a matching
placebo,eachtakenorallyoncedailyfor2
weeks. Following this, all assessments
were repeated. A 2-week washout period
then ensued, after which repeat assess-
ment, a 2-week dose of the other agent
(placebo or allopurinol), and the ﬁnal as-
sessment occurred.
The primary end point was change in
ICA ﬂow induced by the L-NMMA infu-
sionandexpressedasareaundertheﬂow-
per-time curve (AUC) measured from the
start of infusion to 20 min after its com-
pletion(3,4).AnegativeAUCsigniﬁesthe
expected reduction in ICA ﬂow following
L-NMMA infusion. Based on our previous
pilot data (3), a sample of 20 patients
would enable detection of a clinically sig-
niﬁcant improvement in L-NMMA re-
sponsiveness following allopurinol (to
75% of that seen in nondiabetic indi-
viduals) with 90% power (a ´  5%). Sec-
ondary end points were change in
augmentation index (measured during
PWA), PWV, and blood markers.
Standard crossover study analysis
techniques were employed, and differ-
ences between the study periods were
compared using paired nonparametric
tests (Wilcoxon’s signed-rank test). A
positive difference between study periods
represents improvement in favor of allo-
purinol. A mixed-effects model was gen-
erated to adjust for any effect of treatment
ordering.
RESULTS— Fourteen patients were
recruited. Ten completed the protocol;
one had a positive ETT, two failed to at-
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one was unable to receive L-NMMA dur-
ing his last study visit. The study was ter-
minated early as a result of the national
lack of availability of L-NMMA. No ad-
verse events occurred.
Ofthoserecruited,meanSDagewas
53.1  10.8 years, 85.7% (n  12) had
coexisting hypertension, 78.6% (n  11)
were receiving oral hypoglycemic agents,
78.6% were receiving ACE inhibitor or an-
giotensin receptor blocker therapy, 64.3%
were receiving antiplatelet therapy, and
92.3% were on lipid-lowering therapy.
Mean A1C was 6.6  0.94%.
Thebaselineresponseto L-NMMAin-
fusion was impaired. ICA ﬂow fell by a
median of 4.8% (95% CI 17.3 to 9.4;
P  0.25). We saw no change in blood
pressure parameters where AUCs were
considered or in the augmentation index
or PWV following L-NMMA (Table 1 ).
Allopurinol treatment signiﬁcantly
augmented the reduction in ICA ﬂow fol-
lowing L-NMMA infusion (Table 1). ICA
ﬂow fell by a median of 11.9% (95% CI
2.5to23.3;P0.04)following L-NMMA
after treatment with allopurinol. The
mixed-effects model revealed results con-
sistentwiththemainanalysis(P0.046for
allopurinol vs. placebo) and found no sig-
niﬁcantordereffect(P0.51).Allopurinol
led to an improvement in response to L-
NMMA in 8 of the 10 individuals.
The preinfusion augmentation index,
PWV (Table 1), and L-NMMA (data not
shown) did not differ signiﬁcantly be-
tweenthetreatmentperiods(Table1).No
signiﬁcant differences were seen in any of
the blood markers (Table 1).
CONCLUSIONS— L-NMMA re-
ducescerebralbloodﬂowthroughrestric-
tion of NO activity. The higher the basal
NO activity, the larger the effect. Treat-
ment with allopurinol enhanced this ef-
fect, implying that allopurinol improves
basal levels of NO activity, causing them
to approach those previously seen in
healthy volunteers (3).
We saw no improvement in blood
markers or measures of peripheral arte-
rialstiffness.Theseresultscontrastwith
a previous study where forearm blood
ﬂow responses were improved follow-
ing allopurinol (5), but we employed
different techniques and did not design
our study to detect differences in these
parameters. Interestingly, at the base-
line visit, we failed to replicate the in-
crease in the augmentation index or
PWV following L-NMMA seen previ-
ously in healthy volunteers (6), and it
may be that this response is also im-
paired in those with diabetes.
The potential beneﬁcial effects of
allopurinol on the vasculature are two-
fold: it reduces xanthine oxidase–
mediated O2
 production (7) and
reduces serum uric acid (8). Previous
studies have shown a beneﬁcial effect of
xanthine oxidase inhibition on mea-
suresofforearmorcoronaryendothelial
function (9), but this is the ﬁrst human
study to show improvement in cerebro-
vascular function.
We followed a rigorous protocol, and
improvements in peripheral vascular re-
sponses to L-NMMA have been shown
following treatment with other cardio-
vasculature-protective agents (10,11).
However, we studied fewer patients
than intended because of the lack of on-
goingavailabilityof L-NMMA,whichre-
duces our statistical power, but the
consistency of effect we saw is reassur-
ing. Our dosing period was short, and
we cannot exclude the possibility that
the changes we saw may subsequently
be reversed by other sources of O2
.
Also, we have only examined the effect
on endothelial NO synthase activity,
and other forms of NO and O2
 pro-
duction may be important.
In summary, our data show that xan-
thine oxidase inhibition with allopurinol
improves cerebral NO activity, which
may beneﬁt cerebrovascular health. We
encourage further investigation of its use
for stroke prevention.
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